{
  "id": 3949761,
  "title": "Alnylam Pharmaceuticals stock falls on silencer drug concerns",
  "url": "https://urgent.news/2026/08/28/alnylam-pharmaceuticals-stock-falls-on-silencer-drug-concerns",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-28T11:26:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/alnylam-pharmaceuticals-stock-falls-on-silencer-drug-concerns-93CH-4881032"
  },
  "original_language": "en",
  "account": "Alnylam Pharmaceuticals (ALNY) experienced a 6% decline in stock price after AstraZeneca disclosed disappointing results from a Phase 3 clinical trial for an experimental silencer drug targeting ATTR-CM heart condition. The trial, which involved most participants already on a stabilizer drug, showed no significant improvement in patients taking AstraZeneca's drug alongside stabilizers. This outcome raises concerns about the viability of silencer drugs amidst intensifying competition among pharmaceutical companies in the ATTR-CM treatment market, valued to reach multi-billion dollars.",
  "summary": null,
  "key_points": [
    "Alnylam stock drops 6% following AstraZeneca's trial results",
    "Phase 3 trial shows no improvement in ATTR-CM patients",
    "Silencer drug market faces competitive pressure"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}